All Stories

  1. From Acute Infection to Chronic Risk: Reframing Pneumonia Outcomes through Long-Term Mortality Prediction
  2. Corticosteroids in severe community-acquired pneumonia: friend, foe or both?
  3. Transforming post-acute pneumonia management: risk stratification using machine learning
  4. Nuevas perspectivas en la neumonía adquirida en la comunidad en el adulto
  5. Corticosteroids and hospital-acquired pneumonia
  6. The pneumonia challenge: time to end the global neglect
  7. Immunosuppressed patients with COVID-19 pneumonia in ICU: clinical characteristics and factors influencing outcomes
  8. Critical Challenges: Respiratory Infections in Immunocompromised ICU Patients
  9. Pulse oximetry to optimise first-line care and save children’s lives: evidence from the AIRE project in West Africa
  10. Why RSV Infection Matter in Older Adults? The Urgent Need for Vaccination
  11. Pulmonary Infections in Patients with Human Immunodeficiency Virus Infection
  12. Identifying predictors of treatment failure with community-acquired pneumonia: an update
  13. Risk Factors and Outcomes Associated With Polymicrobial Infection in Community-Acquired Pneumonia
  14. Inteligencia Artificial en la identificación de la Neumonía Pediátrica en Radiografías de Tórax
  15. Infecciones por el virus respiratorio sincitial en los adultos
  16. Viral community-acquired pneumonia: what’s new since COVID-19 emerged?
  17. Coronavirus Disease 2019 and Emerging Lung Infections in the Immunocompromised Patient
  18. Adult vaccinations against respiratory infections
  19. Healthcare worker views on antimicrobial resistance in chronic respiratory disease
  20. Mechanical power is not associated with mortality in COVID-19 mechanically ventilated patients
  21. World Pneumonia Day 2024: Fighting Pneumonia and Antimicrobial Resistance
  22. Impact of Empirical Treatment Recommendations From 2017 European Guidelines for Nosocomial Pneumonia
  23. Effect of mesenchymal stem cells on the host response in severe community-acquired pneumonia
  24. Outcomes of corticosteroid therapy in patients with viral community-acquired pneumonia
  25. Epidemiology, ventilation management and outcomes of COVID–19 ARDS patients versus patients with ARDS due to pneumonia in the Pre–COVID era
  26. A review of the value of point-of-care testing for community-acquired pneumonia
  27. Basic host response parameters to classify mortality risk in COVID-19 and community-acquired pneumonia
  28. Diabetes Mellitus and Pneumococcal Pneumonia
  29. The association of premorbid conditions with 6-month mortality in acutely admitted ICU patients over 80 years
  30. Clustering COVID-19 ARDS patients through the first days of ICU admission. An analysis of the CIBERESUCICOVID Cohort
  31. Viral Pneumonia: From Influenza to COVID-19
  32. Pneumococcal Serotypes Associated with Community-Acquired Pneumonia Hospitalizations in Adults in Spain, 2016–2020: The CAPA Study
  33. World Pneumonia Day 2023: the rising global threat of pneumonia and what we must do about it
  34. Clinical Outcomes of Critical COVID-19 in HIV-Infected Adults: A Propensity Score Matched Analysis
  35. Ten Issues for Updating in Community-Acquired Pneumonia: An Expert Review
  36. Systematic review of ceftaroline fosamil in the management of patients with methicillin-resistantStaphylococcus aureuspneumonia
  37. Is the long-term mortality similar in COVID-19 and community-acquired pneumonia?
  38. Impact of outdoor air pollution on severity and mortality in COVID-19 pneumonia
  39. Interventions to improve outcomes in community-acquired pneumonia
  40. The pharmacokinetic evaluation of omadacycline (Oral Only Dosing Regimen) for the treatment of Community-Acquired Bacterial Pneumonia (CABP)
  41. Procalcitonin and C-reactive protein to rule out early bacterial coinfection in COVID-19 critically ill patients
  42. World Pneumonia Day 2023: Reducing the impact of pneumonia in the Americas
  43. A Novel Approach to Temperature Profiling in Relation to Clinical Outcomes in Oncological Patients with Neutropenia
  44. Key Factors Associated With Pulmonary Sequelae in the Follow-Up of Critically Ill COVID-19 Patients
  45. Características clínicas y epidemiológicas de las muertes por dengue durante un brote en el norte del Perú
  46. Immunocompromised Host Pneumonia: Definitions and Diagnostic Criteria: An Official American Thoracic Society Workshop Report
  47. Remdesivir and survival outcomes in critically ill patients with COVID-19: A multicentre observational cohort study
  48. Pneumococcal Vaccination in Adults: What Can We Learn From Observational Studies That Evaluated PCV13 and PPV23 Effectiveness in the Same Population?
  49. Risk factors associated with mortality among elderly patients with COVID-19: Data from 55 intensive care units in Spain
  50. Advances in molecular diagnostic tests for community-acquired pneumonia
  51. Bacterial Patterns and Empiric Antibiotic Use in COPD Patients With Community-Acquired Pneumonia
  52. Machine-Learning Model for Mortality Prediction in Patients With Community-Acquired Pneumonia
  53. Hyperglycemia in Acute Critically Ill COVID-19 Patients
  54. Validation of IDSA/ATS Guidelines for ICU Admission in Adults Over 80 Years Old With Community-Acquired Pneumonia
  55. Estimating the risk of bacteraemia in hospitalised patients with pneumococcal pneumonia
  56. Host-targeted approaches to sepsis due to community-acquired pneumonia
  57. Differences between sexes concerning COVID-19-related pneumonia
  58. Respiratory viruses: their importance and lessons learned from COVID-19
  59. Early Recognition of Low-Risk SARS-CoV-2 Pneumonia
  60. Relationship between corticosteroid use and incidence of ventilator-associated pneumonia in COVID-19 patients: a retrospective multicenter study
  61. Major candidate variables to guide personalised treatment with steroids in critically ill patients with COVID-19: CIBERESUCICOVID study
  62. Outcomes of Critically Ill Very Old Patients With Community-Acquired Pneumonia and Acute Respiratory Distress Syndrome
  63. Aspiration pneumonia
  64. Ceftaroline in severe community-acquired pneumonia
  65. Steroid therapy and antiviral treatment in SARSCoV-2 pneumonia: clinical contexts and indications
  66. Biomarcadores biológicos en las enfermedades respiratorias
  67. [Translated article] Biological Biomarkers in Respiratory Diseases
  68. What's Next in Pneumonia?
  69. Early Initiation of Corticosteroids Might be Harmful in Patients Hospitalized With COVID-19 Pneumonia: A Multicenter Propensity Score Analysis
  70. Severe Infections Due to Respiratory Viruses
  71. One-year mortality after ICU admission due to COVID-19 infection
  72. Invasive pulmonary aspergillosis among intubated patients with SARS-CoV-2 or influenza pneumonia: a European multicenter comparative cohort study
  73. Management of pneumonia in critically ill patients
  74. Real-world corticosteroid use in severe pneumonia: a propensity-score-matched study
  75. COVID-19 in patients aged 80 years and over during the peaks of the first three pandemic waves at a Spanish tertiary hospital
  76. Impact on in-hospital mortality of ceftaroline versus standard of care in community-acquired pneumonia: a propensity-matched analysis
  77. Management and outcomes in critically ill nonagenarian versus octogenarian patients
  78. The evolution of the ventilatory ratio is a prognostic factor in mechanically ventilated COVID-19 ARDS patients
  79. Outcomes of Critically ill Very old patients with Acute Respiratory Distress Syndrome and Community-Acquired Pneumonia
  80. Impact on in-hospital mortality of Ceftaroline versus standard of care in Community-Acquired Pneumonia: A Propensity Matched Analysis
  81. The Value of C-Reactive Protein-to-Lymphocyte Ratio in Predicting the Severity of SARS-CoV-2 Pneumonia
  82. Prediction of ventilator-associated pneumonia outcomes according to the early microbiological response: a retrospective observational study
  83. Early Bacterial Identification among Intubated Patients with COVID-19 or Influenza Pneumonia: A European Multicenter Comparative Clinical Trial
  84. Relationship between the Clinical Frailty Scale and short-term mortality in patients ≥ 80 years old acutely admitted to the ICU: a prospective cohort study
  85. Community-acquired pneumonia severity assessment tools in patients hospitalized with COVID-19: a validation and clinical applicability study
  86. Pulse oximetry is an essential tool that saves lives: a call for standardisation
  87. The COVID-19 puzzle: deciphering pathophysiology and phenotypes of a new disease entity
  88. Provision of critical care for the elderly in Europe: a retrospective comparison of national healthcare frameworks in intensive care units
  89. Relationship between ventilator-associated pneumonia and mortality in COVID-19 patients: a planned ancillary analysis of the coVAPid cohort
  90. Predictive Performance of Risk Factors for Multidrug-Resistant Pathogens in Nosocomial Pneumonia
  91. The Evolution and Distribution of Pneumococcal Serotypes in Adults Hospitalized With Community-Acquired Pneumonia in Spain Using a Serotype-Specific Urinary Antigen Detection Test: The CAPA Study, 2011–2018
  92. Pneumonia
  93. Lymphopenia Is Associated With Poor Outcomes of Patients With Community-Acquired Pneumonia and Sepsis
  94. Trends in mortality of hospitalised COVID-19 patients: A single centre observational cohort study from Spain
  95. Frailty is associated with long-term outcome in patients with sepsis who are over 80 years old: results from an observational study in 241 European ICUs
  96. Validation of a Prediction Score for Drug-Resistant Microorganisms in Community-acquired Pneumonia
  97. Relationship between SARS-CoV-2 infection and the incidence of ventilator-associated lower respiratory tract infections: a European multicenter cohort study
  98. Aspiration Risk Factors, Microbiology, and Empiric Antibiotics for Patients Hospitalized With Community-Acquired Pneumonia
  99. Incidence of co-infections and superinfections in hospitalized patients with COVID-19: a retrospective cohort study
  100. Methicillin-susceptible staphylococcus aureus in community-acquired pneumonia: Risk factors and outcomes
  101. The Value of C-Reactive Protein-to-Lymphocyte Ratio in Predicting the Severity of SARS-CoV-2 Pneumonia
  102. Aetiological diagnosis in new adult outpatients with bronchiectasis:role of predictors derived from real life experience
  103. PES Pathogens in Elderly Patients with Acquired Pneumonia in the Community
  104. Awareness and Pneumonia knowledge: where to start educating?
  105. Methicillin-susceptible Staphylococcus aureus in Community-Acquired Pneumonia: Risk Factors and Outcomes
  106. Systemic Inflammatory Response and Outcomes in Community-Acquired Pneumonia Patients Categorized According to the Smoking Habit or Presence of Chronic Obstructive Pulmonary Disease
  107. SARS-CoV-2–induced Acute Respiratory Distress Syndrome: Pulmonary Mechanics and Gas-Exchange Abnormalities
  108. The importance of airway and lung microbiome in the critically ill
  109. Personalized Therapy Approach for Hospitalized Patients with Coronavirus Disease 2019
  110. Q Fever (Coxiella Burnetii)
  111. Promoting the use of social networks in pneumonia
  112. Difficult to treat microorganisms in patients aged over 80 years with community-acquired pneumonia: the prevalence of PES pathogens
  113. Advances in molecular diagnostic tests for pneumonia
  114. Are Macrolides as Effective as Fluoroquinolones in Legionella Pneumonia? Yes, but…
  115. Bacterial etiology of community-acquired pneumonia in immunocompetent hospitalized patients and appropriateness of empirical treatment recommendations: an international point-prevalence study
  116. Ceftaroline for severe community-acquired pneumonia: A real-world two-centre experience in Italy and Spain
  117. Gender differences in community-acquired pneumonia
  118. Community-acquired pneumonia in critically ill very old patients: a growing problem
  119. Defining Community-Acquired Pneumonia as a Public Health Threat: Arguments in Favor from Spanish Investigators
  120. Can Artificial Intelligence Improve the Management of Pneumonia
  121. Programmed ‘disarming’ of the neutrophil proteome reduces the magnitude of inflammation
  122. A multicentre analysis of Nocardia pneumonia in Spain: 2010–2016
  123. Non-invasive ventilation in palliative care: a systematic review
  124. Reply to Musher
  125. Macrolide combination therapy for hospitalised CAP patients? An individualised approach supported by machine learning
  126. An overview of guidelines for the management of hospital-acquired and ventilator-associated pneumonia caused by multidrug-resistant Gram-negative bacteria
  127. The contribution of frailty, cognition, activity of daily life and comorbidities on outcome in acutely admitted patients over 80 years in European ICUs: the VIP2 study
  128. New antibiotics for community acquired pneumonia
  129. Pneumocystis pneumonia in the twenty-first century: HIV-infected versus HIV-uninfected patients
  130. Prevalence and risk factors of sepsis in very old patients with CAP
  131. Effect of Corticosteroids on C-Reactive Protein in Patients with Severe Community-Acquired Pneumonia and High Inflammatory Response: The Effect of Lymphopenia
  132. Ventilator-Associated Pneumonia and PaO2/FIO2 Diagnostic Accuracy: Changing the Paradigm?
  133. Prevalence and risk factors for Enterobacteriaceae in patients hospitalized with community‐acquired pneumonia
  134. Pregnancy as a risk factor for severe influenza infection: an individual participant data meta-analysis
  135. Impact of Cefotaxime Non-susceptibility on the Clinical Outcomes of Bacteremic Pneumococcal Pneumonia
  136. Risk and Prognostic Factors in Very Old Patients with Sepsis Secondary to Community-Acquired Pneumonia
  137. non invasive diagnosis of nosocomial pneumonia
  138. Impact of Cefotaxime Non-susceptibility on the Clinical Outcomes of Bacteremic Pneumococcal Pneumonia
  139. Risk and Prognostic Factors in Very Old Patients with Sepsis Secondary to Community-Acquired pneumonia
  140. lymphopenia predicts mortality in patients with ICU pneumonia
  141. Addendum: Cillóniz, C.; Dominedò, C.; Nicolini, A.; Torres, A. PES Pathogens in Severe Community-Acquired Pneumonia. Microorganisms 2019, 7, 49
  142. Evaluation of the Magicplex™ Sepsis Real-Time Test for the Rapid Diagnosis of Bloodstream Infections in Adults
  143. Multidrug Resistant Gram-Negative Bacteria in Community-Acquired Pneumonia
  144. PES Pathogens in Severe Community-Acquired Pneumonia
  145. An international perspective on hospitalized patients with viral community-acquired pneumonia
  146. Early noninvasive ventilation treatment for respiratory failure due to severe community-acquired pneumonia
  147. Community-acquired pneumonia as an emergency condition
  148. Effect of Combined β-Lactam/Macrolide Therapy on Mortality According to the Microbial Etiology and Inflammatory Status of Patients with Community-Acquired Pneumonia
  149. Reply to Head and Keynan
  150. Drugs that increase the risk of community-acquired pneumonia: a narrative review
  151. Treating HIV-Positive/Non-AIDS Patients for Community-Acquired Pneumonia with ART
  152. Clinical Approach to Community-acquired Pneumonia
  153. Corticosteroid treatment in critically ill patients with severe influenza pneumonia: a propensity score matching study
  154. Inflammatory response depends on time since onset of symptoms in pneumonia
  155. MagicplexTM Sepsis real-time test for the rapid diagnosis of bloodstream infections in adults
  156. Twenty-year trend in mortality among hospitalized patients with pneumococcal community-acquired pneumonia
  157. Burden and risk factors forPseudomonas aeruginosacommunity-acquired pneumonia: a multinational point prevalence study of hospitalised patients
  158. Community-acquired bacterial pneumonia in adult HIV-infected patients
  159. Microorganisms resistant to conventional antimicrobials in acute exacerbations of chronic obstructive pulmonary disease
  160. Community-acquired Pneumonia and Acute Respiratory Distress Syndrome
  161. Characteristics and Management of Community-Acquired Pneumonia in the Era of Global Aging
  162. Community-Acquired Legionella Pneumonia in Human Immunodeficiency Virus–Infected Adult Patients: A Matched Case-Control Study
  163. Burden of pneumococcal community-acquired pneumonia in adults across Europe: A literature review
  164. Effectiveness of combination therapy versus monotherapy with a third-generation cephalosporin in bacteraemic pneumococcal pneumonia: A propensity score analysis
  165. Acute respiratory distress syndrome in mechanically ventilated patients with community-acquired pneumonia
  166. Detection of human cytomegalovirus in bronchoalveolar lavage of intensive care unit patients
  167. Severe community-acquired pneumonia: Characteristics and prognostic factors in ventilated and non-ventilated patients
  168. New Sepsis Definition (Sepsis-3) and Community-acquired Pneumonia Mortality. A Validation and Clinical Decision-Making Study
  169. Respiratory infection: insights from Assembly 10 of the European Respiratory Society 2017 Annual Congress
  170. Has Mortality of Community-Acquired Pneumonia Really Reduced?
  171. Predictors of treatment failure and clinical stability in patients with community acquired pneumonia
  172. Adjuvant therapies in critical care: steroids in community-acquired pneumonia
  173. Investigational drugs in phase I and phase II clinical trials for the treatment of community-acquired pneumonia
  174. Lymphopenic Community Acquired Pneumonia (L-CAP), an Immunological Phenotype Associated with Higher Risk of Mortality
  175. Evaluation of severity score-guided approaches to macrolide use in community-acquired pneumonia
  176. The burden of PCV13 serotypes in hospitalized pneumococcal pneumonia in Spain using a novel urinary antigen detection test. CAPA study
  177. Time to blood culture positivity as a predictor of clinical outcomes and severity in adults with bacteremic pneumococcal pneumonia
  178. Community-Acquired Pneumococcal Pneumonia in Virologically Suppressed HIV-Infected Adult Patients
  179. Treatment with macrolides and glucocorticosteroids in severe community-acquired pneumonia: A post-hoc exploratory analysis of a randomized controlled trial
  180. Invasive Disease vs Urinary Antigen-Confirmed Pneumococcal Community-Acquired Pneumonia
  181. Risk factors for community-acquired pneumonia in adults
  182. Antibiotic therapy prior to hospital admission is associated with reduced septic shock and need for mechanical ventilation in patients with community-acquired pneumonia
  183. Typical Presentation of Legionella pneumophila Community-Acquired Pneumonia
  184. Research in community-acquired pneumonia: the next steps
  185. Seasonality of pathogens causing community-acquired pneumonia
  186. Microbial Etiology of Pneumonia: Epidemiology, Diagnosis and Resistance Patterns
  187. Laboratory diagnosis of pneumonia in the molecular age
  188. Delay in diagnosis of influenza A (H1N1)pdm09 virus infection in critically ill patients and impact on clinical outcome
  189. Clinical management of community acquired pneumonia in the elderly patient
  190. Community-Acquired Pneumonia 2000-2015: What is New?
  191. Response
  192. Community-Acquired Pneumonia Due to Multidrug- and Non–Multidrug-Resistant Pseudomonas aeruginosa
  193. Community-acquired pneumonia related to intracellular pathogens
  194. Predictive and prognostic factors in patients with blood-culture-positive community-acquired pneumococcal pneumonia
  195. What is the clinical relevance of drug-resistant pneumococcus?
  196. Multilobar bilateral and unilateral chest radiograph involvement: implications for prognosis in hospitalised community-acquired pneumonia
  197. Pneumococcal vaccination
  198. Impact of neuraminidase inhibitors on influenza A(H1N1)pdm09-related pneumonia: an individual participant data meta-analysis
  199. Procalcitonin (PCT) levels for ruling-out bacterial coinfection in ICU patients with influenza: A CHAID decision-tree analysis
  200. Severe community-acquired pneumonia: Corticosteroids as adjunctive treatment to antibiotics
  201. Bronchiectasis in rare pulmonary diseases: A case series
  202. Bacteraemia in outpatients with community-acquired pneumonia
  203. Polymicrobial community-acquired pneumonia: An emerging entity
  204. Sensitivity, Specificity, and Positivity Predictors of the Pneumococcal Urinary Antigen Test in Community-Acquired Pneumonia
  205. Bacteraemia in outpatient with community-acquired pneumonia
  206. Ceftobiprole for the treatment of pneumonia: a European perspective
  207. Streptococcus pneumoniae-associated pneumonia complicated by purulent pericarditis: case series
  208. Microbiology and outcomes of community acquired pneumonia in non cystic-fibrosis bronchiectasis patients
  209. New antimicrobial approaches to gram positive respiratory infections
  210. Macrolide resistance and outcomes of patients with Streptococcus pneumoniae pneumonia.
  211. Risk Factors Associated with Potentially Antibiotic-Resistant Pathogens in Community-Acquired Pneumonia
  212. Bacteraemia and antibiotic-resistant pathogens in community acquired pneumonia: risk and prognosis
  213. Severe community-acquired pneumonia: Severity and management
  214. Noninvasive ventilation for acute respiratory failure due to community-acquired pneumonia: A concise review and update
  215. Clinical Management of Bacterial Pneumonia
  216. Viral infections
  217. Detection of Pneumonia Associated Pathogens Using a Prototype Multiplexed Pneumonia Test in Hospitalized Patients with Severe Pneumonia
  218. Severity and outcomes of community acquired pneumonia in asthmatic patients
  219. Predicting treatment failure in patients with community acquired pneumonia: a case-control study
  220. Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data
  221. Lung abscess due to Streptococcus pneumoniae: a case series and brief review of the literature
  222. Epidemiology, antibiotic therapy and clinical outcomes of healthcare-associated pneumonia in critically ill patients: a Spanish cohort study
  223. Community-acquired lung respiratory infections in HIV-infected patients: microbial aetiology and outcome
  224. IgA level in plasma as a differential factor for influenza infection in severe viral pneumonia
  225. Pneumococcal disease: Epidemiology and new vaccines
  226. Community-acquired viral pneumonia in human immunodeficiency virus infected patients
  227. Phenotyping community-acquired pneumonia according to the presence of acute respiratory failure and severe sepsis
  228. Predicting Community-Acquired Pneumonia Etiology: Response
  229. A Worldwide Perspective of Nursing Home-Acquired Pneumonia Compared With Community-Acquired Pneumonia
  230. IgM levels in plasma predict outcome in severe pandemic influenza
  231. Microbial aetiology of healthcare associated pneumonia in Spain: a prospective, multicentre, case–control study
  232. Impact of Age and Comorbidity on Cause and Outcome in Community-Acquired Pneumonia
  233. Multidrug-resistant pathogens in hospitalised patients coming from the community with pneumonia: a European perspective: Table 1
  234. Influence of Previous Use of Inhaled Corticoids on the Development of Pleural Effusion in Community-acquired Pneumonia
  235. Thrombocytosis Is a Marker of Poor Outcome in Community-Acquired Pneumonia
  236. Epidemiology, Clinical Features, and Prognosis of Elderly Adults with Severe Forms of Influenza A (H1N1)
  237. Systemic corticosteroids for community-acquired pneumonia: Reasons for use and lack of benefit on outcome
  238. Macrolide-based regimens in absence of bacterial co-infection in critically ill H1N1 patients with primary viral pneumonia
  239. Influenza A (H1N1) Pneumonia
  240. Pulmonary complications of pneumococcal community-acquired pneumonia: incidence, predictors, and outcomes
  241. Invasive Pneumococcal Disease Today
  242. Bacterial co-infection with H1N1 infection in patients admitted with community acquired pneumonia
  243. Entendimento da mortalidade em pneumonia pneumocócica bacterêmica
  244. Cytokine Activation Patterns and Biomarkers Are Influenced by Microorganisms in Community-Acquired Pneumonia
  245. Pulmonary Complications Of Pneumococcal CAP: Incidence, Predictors, And Outcomes
  246. Corticosteroids In Community-Acquired Pneumonia: Therapeutic Reasons And Outcomes
  247. Influence Of Long-Term Use Of Inhaled Corticoids On The Development Of Pleural Effusion In Community Acquired Pneumonia
  248. Thrombocytosis Is A Diagnostic And Prognostic Marker In Community-Acquired Pneumonia
  249. Corticosteroid therapy in patients with primary viral pneumonia due to pandemic (H1N1) 2009 influenza
  250. Community-acquired pneumonia in outpatients: aetiology and outcomes
  251. CD4+ cell counts and HIV-RNA levels do not predict outcomes of community-acquired pneumonia in hospitalized HIV-infected patients
  252. CAP IN COPD PATIENTS
  253. Clinical relevance of mixed respiratory viral infections in adults with influenza A H1N1
  254. First influenza season after the 2009 pandemic influenza: report of the first 300 ICU admissions in Spain
  255. Microbial aetiology of community-acquired pneumonia and its relation to severity
  256. Community-acquired polymicrobial pneumonia in the intensive care unit: aetiology and prognosis
  257. Pandemic and post-pandemic Influenza A (H1N1) infection in critically ill patients
  258. Influenza pneumonia: a comparison between seasonal influenza virus and the H1N1 pandemic
  259. Correction
  260. Factors associated with inflammatory cytokine patterns in community-acquired pneumonia
  261. Severe Mixed Community Acquired Pneumoniae
  262. Community-acquired Pneumonia In Outpatients: Microbial Etiology
  263. INDICATION OF PLEURAL DRAINAGE IN PARAPNEUMONIC EFFUSION: ADHERENCE TO THE AMERICAN COLLEGE OF CHEST PHYSICIANS’ GUIDELINES
  264. PARAPNEUMONIC EFFUSIONS ACCORDING TO THE CLASSIFICATION OF THE AMERICAN COLLEGE OF CHEST PHYSICIANS: CLINICAL CHARACTERISTICS
  265. Healthcare-associated Pneumonia (HCAP): Clinical Features And Biomarkers
  266. Nursing home-acquired pneumonia: a 10 year single-centre experience
  267. Impact of Smoking Habit on the Etiology of Community-Acquired Pneumonia (CAP).
  268. Community-Acquired Pneumonia: Etiology and Severity Scores.
  269. Complicated Pneumococcal Pneumonia in Adults.
  270. Severe community-acquired pneumonia